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OBJECTIVES: N-3 polyunsaturated fatty acids have been proposed as a novel treatment for preventing postoperative
atrial fibrillation due to their potential anti-inflammatory and anti-arrhythmic effects. However, randomized studies
have yielded conflicting results. The objective of this study is to review randomized trials of N-3 polyunsaturated
fatty acid use for postoperative atrial fibrillation.
METHODS: Using the CENTRAL, PUBMED, EMBASE, and LILACS databases, a literature search was conducted to
identify all of the studies in human subjects that reported the effects of N-3 polyunsaturated fatty acids on the
prevention of postoperative atrial fibrillation in cardiac surgery patients. The final search was performed on January
30, 2011. There was no language restriction, and the search strategy only involved terms for N-3 polyunsaturated
fatty acids (or fish oil), atrial fibrillation, and cardiac surgery. To be included, the studies had to be randomized
(open or blinded), and the enrolled patients had to be $18 years of age.
RESULTS: Four randomized studies (three double-blind, one open-label) that enrolled 538 patients were identified.
The patients were predominantly male, the mean age was 62.3 years, and most of the patients exhibited a normal
left atrial size and ejection fraction. N-3 polyunsaturated fatty acid use was not associated with a reduction in
postoperative atrial fibrillation. Similar results were observed when the open-label study was excluded.
CONCLUSIONS: There is insufficient evidence to suggest that treatment with N-3 polyunsaturated fatty acids reduces
postoperative atrial fibrillation. Therefore, their routine use in patients undergoing cardiac surgery is not recommended.
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INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia
following cardiac surgery. Its incidence ranges from 20 to
70%, depending on the patient age and the complexity of the
surgical procedure.1-3 Although well tolerated in most cases,
postoperative AF is associated with prolonged hospitaliza-
tion, increased costs, morbidity, and mortality.4-6
The etiology of postoperative AF is multifactorial, and
although several risk factors are associated with this
condition, the underlying mechanisms are controversial.
Furthermore, antiarrhythmic drugs have not been effective
in preventing postoperative AF.2
Recent clinical and experimental studies have shown that
N-3 polyunsaturated fatty acids (PUFAs) are effective in
preventing AF,7,8 and PUFAs have been used to prevent AF
in patients undergoing cardiac surgery. However, the
studies supporting this treatment have reported conflicting
results on its efficacy in preventing postoperative AF.9-13
The objective of this analysis is to estimate the effect of
PUFA on preventing postoperative AF through a meta-
analysis of randomized controlled clinical trials.
METHODS
Study Search
Using the Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library, Issue 3, 2008), PUBMED,
EMBASE, and LILACS databases, a literature search was
conducted to identify all of the studies that reported the
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effects of PUFAs on the prevention of postoperative AF in
human cardiac surgery patients. The final literature search
was performed on January 30th, 2011. To maximize the
sensitivity, no language restriction was used, and the search
strategy involved only terms for PUFA (or fish oil), AF, and
cardiac surgery. All of the included studies were rando-
mized, both open and blinded studies were considered, and
the enrolled patients had to be $18 years of age. In addition,
the reference lists from the included studies were scrutinized
to identify additional citations and specialists in the field, and
the authors of the included publications were contacted and
asked for unpublished data to avoid publication bias.
Data Abstraction
The outcome of interest was the occurrence of AF. Two
reviewers (LA and JSH) independently screened, extracted
data from, and performed quality assessment of the cohort
trials identified by the literature search. Any disagreements
between the examiners were settled by consensus. A funnel
plot of the results was generated to detect any publication
bias. Figure 1 demonstrates the study selection process
according to the PRISMA flow diagram.
Definition of Atrial Fibrillation
The definition of AF varied between the studies. Calo
et al.9 defined postoperative AF as any electrocardiographi-
cally confirmed episode of AF of more than 5 minutes in
duration or requiring intervention for angina or compro-
mised hemodynamics during the hospitalization period. In
the Heidt study,11 AF was detected by monitoring or 12-lead
electrocardiography during the intensive care unit period
and was defined as any confirmed episode of AF lasting
$15 minutes. In the Heidarsdottir study,12 all of the patients
underwent continuous electrocardiographic monitoring
during hospitalization, and postoperative AF was defined
as any episode lasting more than 5 minutes. The patients
exited the study upon discharge from the hospital or two
weeks after the surgery. Finally, Saravanan et al.13 defined
AF as any episode lasting $30 seconds in the monitor
recording (primary outcome). Clinically recognized AF (as
documented in the patient’s clinical records by the treating
clinician) and the AF burden (defined as the percentage of
time that a given patient had AF) were the secondary
outcomes.
Statistical Analysis
The individual unit of analysis was the patient (not
patient-years). Heterogeneity was evaluated using the
Cochran Q and chi-squared tests. For the purpose of this
analysis, we interpreted a chi-squared of $25 as indicative
of significant heterogeneity. All of the analyses were
performed according to the intention-to-treat principle.
The overall treatment effects were reported via odds ratios
with 95% confidence intervals. Random effects modeling
with the Mantel-Haenszel test was performed to generate a
pooled estimate of the effect of PUFA treatment on
postoperative AF. To exclude ascertainment bias and any
potential confounding due to concomitant treatments in
open-label designs, we performed a sensitivity analysis that
excluded the open-label trial. The statistical testing was two-
tailed, and statistical significance was defined as p,0.05. All
of the statistical analyses were conducted with the R
Development Core Team software.
RESULTS
Search Results
Four clinical studies (538 patients) reporting the effects
of PUFAs on the prevention of postoperative AF were
identified and included in the final analyses of this
study.9,11-13 Of the four studies, two12,13 reported no effects
on postoperative AF, and two9,11 reported a significant
reduction in the incidence of AF shortly after cardiac
surgery.
Study Characteristics and Study Quality
The characteristics of the studies are summarized in
Table 1. Most of the studies used encapsulated fish oil, but
one11 examined the effects of intravenously administered n-
3 fatty acids. Two studies12,13 had a placebo control, one11
administered saturated fatty acids as a control, and the
other one9 enrolled patients who had not received PUFA as
the control group. The Calo,9 Heidt,11 and Saravanan13
studies included patients who were .18 years of age, while
Heidarsdottir12 included all consecutive patients who were
.40 years old and scheduled for elective or urgent (not
emergent) open heart surgery. The Calo9 and Heidt11
studies excluded patients with unstable hemodynamic
conditions before surgery, and Saravanan13 included
patients who underwent elective isolated coronary artery
bypass graft surgery. Calo,9 Heidt,11 and Saravanan13 all
excluded concomitant valvular surgery.
Baseline Patient Characteristics
The preoperative baseline characteristics are shown in
Table 2. In general, the patients in both control and study
groups tended to be male with a mean age of 62.3 years.
Most of the patients in all of the studies had a normal left
atrial size and ejection fraction. Systemic hypertension was
more frequently observed in the Calo9 and Heidarsdottir12
populations. The concomitant use of beta-blockers was more
common in the Heidarsdottir12 and Saravanan13 studies.Figure 1 - The PRISMA flow diagram.
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Atrial Fibrillation and Clinical Outcomes
Figure 2 shows a forest plot comparing the total mortality
of the patients that received PUFAs to those that did not
receive PUFAs. The use of PUFAs was not associated with a
reduction in the occurrence of postoperative AF in the
patients undergoing cardiac surgery compared to the
untreated patients (odds ratio, 0.79; 95% confidence interval,
0.56 - 1.13; p= 0.195). Similar results were observed when
the open-label study was excluded from the analyses (odds
ratio, 0.99; 95% confidence interval, 0.65 - 1.49; p= 0.963).
Heidarsdottir et al.12 reported no differences in the post-
operative outcomes (such as blood transfusion, the re-
operation frequency, and major bleeding) between the
groups. Two patients in the PUFA group died. One patient
died due to a massive myocardial infarction and heart
failure three days after surgery, and another patient died
from an ascending aortic rupture two days after surgery.
One patient in the PUFA arm and three patients in
the placebo group suffered cerebrovascular accidents.
Gastrointestinal discomfort was more common in the
PUFA group and resulted in the discontinuation of two
patients. In the Calo9 study, no significant adverse reactions
were observed in the PUFA patients, except for a single case
of an allergic reaction, and there were no differences in the
incidence of non-fatal complications or death between the
groups. In both this study and in the study by Heidt et al.,11
PUFA treatment was associated with a shorter hospital stay.
In contrast, Saravanan et al.13 found no difference in the
length of the hospital stay between the groups. No drug-
related complications were reported by Saravanan et al.13
DISCUSSION
This analysis showed no benefit of PUFAs for reducing
AF following cardiac surgery.
Although several strategies involving PUFAs have been
developed for preventing postoperative AF, none have
proven its efficacy or justify its routine use in this setting.
Clinical and experimental studies have shown that the
administration of PUFAs reduces major cardiac events,
including sudden cardiac death, ventricular fibrillation, and
AF.14-16 In a cohort of 4815 patients with 12 years of follow-
up, Mozaffarian et al.17,18 demonstrated that fish intake is
associated with a lower incidence of AF.
Several studies have demonstrated the protective effect of
PUFAs against ventricular arrhythmias. Hyperpolarization
of the resting membrane potential and an increase in the
phase-4 refractory period have been postulated to be the
main antiarrhythmic effects of PUFAs.7,19 Moreover, PUFAs
have been shown to reduce the asynchronous contractile
activity of myocytes,20 increase electrical stability by
prolonging the inactivation of fast outward sodium chan-
nels, and modulate calcium release as a result of
their direct interaction with the sarcoplasmic reticulum.
Table 1 - Studies characteristics.
Results (POAF)
Study N Study design Control Inclusion criteria Exclusion criteria PUFA Control
Calo 160 Open-label, prospective,
randomized, controlled
trial with parallel groups;
not blinded
No PUFA Age .18, NSR, stable
hemodynamic conditions
before surgery
Concomitant valvular surgery, a
prior history of any SVT, the
current use of an AAD other
than BB, CCB, or digitalis
15.2% 33.3%
Heidt 102 Prospective, randomized
double-blinded trial
IV saturated free
fatty acids
Age .18, NSR, stable
hemodynamic conditions
before surgery, no angina
at rest
Concomitant valvular surgery, a
prior history of any SVT, the
current use of an AAD other
than BB or CCB
17.3% 30.6%
Heidarsdottir 168 Prospective, randomized,
double-blinded, placebo-
controlled trial
Placebo All of the consecutive
patients scheduled for
elective or open heart
surgery
Age ,40, prior history of any
SVT, the current use of
amiodarone or sotalol, an
emergent operation
54.2% 54.1%
Saravanan 103 Prospective, randomized,
double-blinded, placebo-
controlled trial
Placebo Age .18, scheduled to
undergo elective isolated
CABG
A prior history of any atrial
arrhythmia, the current use of a
class-1 or class-3 AAD, fish oil
use within 3 mos prior to
surgery
56% 43%
AAD, antiarrhythmic drugs; BB, beta-blockers; CABG, coronary artery bypass grafting; CCB, calcium channel blockers; IV, intravenous; NSR, normal sinus
rhythm; POAF, postoperative atrial fibrillation; PUFA, polyunsaturated fatty acid; SVT, supraventricular tachycardia.
Table 2 - Baseline characteristics.
Age Male (%) LA (mm) EF (%) HTN (%) Beta-blocker (%)
Control PUFA Control PUFA Control PUFA Control PUFA Control PUFA Control PUFA
Calo 64.9¡9.1 66.2¡8.0 84 86 39.7¡5.2 39.7¡5.1 55.3¡11.4 56.3¡12.1 81.5 78.5 56.8 58.2
Heidt NR NR 64 73 40.5¡5.1 40.0¡5.1 52.3¡15.6 52.0¡15.0 NR NR NR NR
Heidarsdottir 67 (43, 82) 67 (45, 82) 76.9 81.9 NR NR 60 (15, 77.5) 60 (15, 70) 64.7 61.4 74.1 78.3
Saravanan 68 (64, 73) 64 (58, 71) 82 77 6% had
LA$2.3
cm/m2
4% had
LA$2.3 cm/
m2
8% had
EF#55%
10% had
EF#55%
29 35 82 88
The values are presented as the mean ¡ standard deviation or as the median (25th, 75th), unless otherwise indicated. EF, ejection fraction; HTN,
hypertension; LA, left atrium; NR, not reported; PUFA, polyunsaturated fatty acid.
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However, other studies have demonstrated that PUFAs
shorten the effective refractory period and action poten-
tial,21-23 which favors the initiation and maintenance of AF.
In fact, a few experimental studies have demonstrated a
pro-arrhythmic effect of PUFAs.24,25 In terms of adverse side
effects, the studies reported different outcomes and results,
but in general, PUFAs do not seem to be directly associated
with any bleeding or ischemic complications.
Clinical studies have reported several benefits of PUFA
treatment for chronic and acute inflammation.26-28 EPA and
DHA can inhibit the conversion of arachidonic acid to
prostaglandin E2 and leukotriene B4, and they also decrease
the synthesis of tumor necrosis factor alpha and interleukin-
1 beta.29 The trauma caused by surgery initiates both local
and systemic inflammatory responses, reflected by
increased C-reactive protein levels. Moreover, it is possible
that local atrial inflammation may produce atrial conduction
abnormalities and consequent reentrant arrhythmias. In a
study conducted by Halonen et al.,30 the administration of
intravenous hydrocortisone reduced the incidence of AF
after cardiac surgery, suggesting that an exaggerated
inflammatory response could be an etiological factor for
the development of postoperative AF. A study by
Mariscalco et al.10 showed higher white blood cell counts
after surgery in patients affected by early AF and lower
levels of postoperative C-reactive protein levels in the
PUFA-treated group, suggesting that PUFAs have anti-
inflammatory properties. This was contradicted by a study
by Saravanan,13 which showed that C-reactive protein levels
were not affected by PUFAs. This discrepancy might be due
to the low doses of PUFAs used in this study, which may
have been below the threshold required to exert any anti-
inflammatory effects. Interestingly, patients in the Calo et al.
study population were more likely to have a history of
myocardial infarction and/or off-pump surgery. This might
also explain the better response to PUFA therapy in this
study compared to other studies.
Calo et al.9 first demonstrated that PUFA administration
during hospitalization significantly reduced the occurrence
of postoperative AF in patients undergoing coronary artery
bypass graft surgery (18.1% absolute risk reduction [RR];
54.4% relative RR) and was associated with a shorter
hospital stay (7.3¡2.1 days vs. 8.2¡2.6 days for PUFA
patients and control patients, respectively; p= 0.017). In the
multivariable analysis, age and the use of PUFAs were
significant independent predictors of postoperative AF.
However, this study was not blinded or placebo-controlled,
and it excluded patients undergoing valvular surgery and
those with a history of AF, which are factors that increase
the risk for postoperative AF. Another limitation of this
study was that the patients in the PUFA group were
hospitalized for fewer days and may have had unidentified
asymptomatic AF after discharge.
The results of this study are congruent with those found
by Heidt.11 Only patients undergoing coronary artery
bypass graft procedures were included in that study. The
patients treated with PUFAs developed significantly less AF
than control patients (17.3% vs. 30.6%, respectively; p,0.05).
More recently, Mariscalco et al. demonstrated that pre-
operative PUFA therapy is associated with a decreased
incidence of early AF after cardiac surgery but does not
prevent late AF. PUFA administration was independently
associated with a 46% relative reduction in the risk of early
AF development (OR, 0.54; 95% CI, 0.31–0.92). This study
included coronary artery bypass surgery procedures and
valve repair, combined surgeries, and other types of cardiac
surgery. Independent predictors of early AF were age, the
left atrial area, reoperation, and the use of an intra-aortic
balloon pump. However, this study was limited by its lack
of randomization; therefore, a causal relationship between
PUFAs and postoperative AF cannot be accurately assessed.
Contrary to previous studies, two recent, randomized,
double-blind, and placebo-controlled studies failed to
demonstrate any beneficial effects of PUFA administra-
tion.12,13 In addition, the recently published Efficacy and
Safety of Prescription Omega-3 Acid Ethyl Esters (P-OM3) for
the Prevention of Recurrent Symptomatic Atrial Fibrillation trial
showed similar results. This was a prospective, randomized,
and double-blinded trial of 663 AF patients (average age, 61
years; 56% male) enrolled at 96 sites in which the use of a
fish oil-derived product (4 grams/day) was compared to the
use of a placebo.31 The two main findings of this study were
that the paroxysmal AF patients who received omega-3 did
not differ significantly from the patients of the placebo
group in terms of the time to the first recurrence of
symptoms, and there was no significant difference in
persistent AF between the treated and placebo groups.
Differences in the patient profiles, the type of surgery, the
definition of arrhythmia, and the method of arrhythmia
surveillance could explain the contradictory results of these
studies. In particular, the method used to evaluate the
occurrence of AF and its burden had the most significant
effect. Calo et al.9 and Heidarsdottir et al.12 defined AF as
any episode lasting more than 5 minutes, Heidt et al.11 used
a cutoff of 15 minutes and Saravanan et al.13 used a cutoff of
30 seconds. This difference likely explains the higher overall
incidence of AF in the latter study.
The method of rhythm surveillance (continuous monitor-
ing vs. electrocardiogram monitoring only if symptoms
are present) might also affect the detection of AF.
Unsurprisingly, the occurrence of AF was higher in the
Figure 2 - A meta-analysis of the randomized studies examining
the incidence of postoperative atrial fibrillation.
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studies that used continuous electrocardiographic monitor-
ing, which was observed in the Saravanan sample.
Another important issue that must be considered is the
concomitant use of beta-blockers and statins. In Calo et al.,9
for example, the percentage of patients taking both drugs
was much lower than in Saravanan et al. (57.5% on beta-
blockers and 56.9% on statins compared to 85% and 98%,
respectively). This may have offset the beneficial effects of
PUFAs in the Saravanan population (Table 3).
CLINICAL IMPLICATIONS
Atrial fibrillation is the most common arrhythmia follow-
ing cardiac surgery, and inflammation plays a role in its
genesis. PUFAs have some anti-inflammatory properties
and antiarrhythmic effects. However, this meta-analysis
showed that PUFA treatment is not associated with a
reduction in the incidence of AF following cardiac surgery.
Thus, the routine use of PUFAs in patients undergoing
cardiac surgery for the prevention of postoperative AF is not
recommended.
LIMITATIONS
Our study has some limitations. The major limitation is
the clinical and statistical heterogeneity of the included
studies. To overcome this degree of heterogeneity, it would
be necessary to perform a large and adequately powered
randomized study, which would be difficult to be con-
ducted and expensive. Therefore, the lack of statistical
power and the heterogeneity among the studies could, in
part, have explained our findings. We only included
randomized studies because they are the gold standard for
assessing treatment effects. However, the population
involved in randomized clinical trials is usually strictly
selected and might not reflect the true profiles of the
patients treated in clinical practice. Thus, caution should
be taken when extrapolating our results to this setting.
Furthermore, we could not systematically assess the adverse
events associated with PUFA treatment because these
outcomes were not systematically and consistently reported
in the included studies. Various fatty acids and dosages
were used in the studies, and we were unable to investigate
the influence of the duration and dosage of preoperative
PUFA treatment and its effects on the incidence of post-
operative AF. The definition of AF also varied among the
studies, which could have affected our findings. Finally, the
overall incidence of postoperative AF depended on the type
and duration of the monitoring techniques, which varied
among the studies.
Despite the heterogeneity of the studies included in our
analysis, we demonstrated that there is currently insuffi-
cient evidence to suggest that PUFA treatment reduces AF
following cardiac surgery. In addition, little information on
the adverse events associated with PUFA treatment is
available. A large, multicenter, randomized trial with well-
defined clinical outcomes and a consistent method of
detection of postoperative AF is still needed to assess the
potential effect of PUFAs on postoperative AF and its
potential adverse outcomes.
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